KPCB PANDEMIC & BIO DEFENSE FUND LLC 4

Accession 0001104659-23-082737

CIK 0001400118other

Filed

Jul 19, 8:00 PM ET

Accepted

Jul 20, 4:20 PM ET

Size

27.8 KB

Accession

0001104659-23-082737

Form 4

Period: 2023-07-18

10% Owner

Transactions

Conversion
Series C Preferred Stock
2023-07-18−8,596,589→ 0 total(indirect: See footnote)
→ Common Stock (108,163 underlying)
Conversion
Series E Preferred Stock
2023-07-18−103,127,234→ 0 total(indirect: See footnote)
→ Common Stock (1,297,549 underlying)
Conversion
Series D Preferred Stock
2023-07-18−6,103,580→ 0 total(indirect: See footnote)
→ Common Stock (76,796 underlying)
Other
Series A Common Stock
2023-07-18+38,763→ 38,763 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2023-07-18−539,006→ 0 total(indirect: See footnote)
→ Common Stock (6,781 underlying)
Other
Common Stock
2023-07-18−38,763→ 0 total(indirect: See footnote)
Conversion
Series A Common Stock
2023-07-18+1,860,712→ 1,899,475 total(indirect: See footnote)
Conversion
Series F Preferred Stock
2023-07-18−20,430,107→ 0 total(indirect: See footnote)
→ Common Stock (257,052 underlying)
Conversion
Series B Preferred Stock
2023-07-18−493,370→ 0 total(indirect: See footnote)
→ Common Stock (6,208 underlying)
Conversion
Series B-1 Preferred Stock
2023-07-18−8,596,590→ 0 total(indirect: See footnote)
→ Common Stock (108,163 underlying)

10% Owner

Transactions

Other
Series A Common Stock
2023-07-18+38,763→ 38,763 total(indirect: See footnote)
Conversion
Series A Common Stock
2023-07-18+1,860,712→ 1,899,475 total(indirect: See footnote)
Conversion
Series D Preferred Stock
2023-07-18−6,103,580→ 0 total(indirect: See footnote)
→ Common Stock (76,796 underlying)
Conversion
Series F Preferred Stock
2023-07-18−20,430,107→ 0 total(indirect: See footnote)
→ Common Stock (257,052 underlying)
Other
Common Stock
2023-07-18−38,763→ 0 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2023-07-18−539,006→ 0 total(indirect: See footnote)
→ Common Stock (6,781 underlying)
Conversion
Series B Preferred Stock
2023-07-18−493,370→ 0 total(indirect: See footnote)
→ Common Stock (6,208 underlying)
Conversion
Series B-1 Preferred Stock
2023-07-18−8,596,590→ 0 total(indirect: See footnote)
→ Common Stock (108,163 underlying)
Conversion
Series C Preferred Stock
2023-07-18−8,596,589→ 0 total(indirect: See footnote)
→ Common Stock (108,163 underlying)
Conversion
Series E Preferred Stock
2023-07-18−103,127,234→ 0 total(indirect: See footnote)
→ Common Stock (1,297,549 underlying)

Footnotes (3)

[F1]Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was reclassified into one share of Series A Common Stock.
[F2]Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted into on a 79.4784-to-one basis into Series A Common Stock. The Preferred Stock had no expiration date.
[F3]Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". KPCB PBD Associates disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

Documents

1 file

Sagimet Biosciences Inc.

CIK 0001400118

Entity typeother